![Photo of the Columns at the University of Missouri with blue sky behind them.](/sites/default/files/styles/feature_image/public/2024-02/bayer_columns_920.jpg?itok=GwbB-VQM)
The University of Missouri is partnering with Bayer to study the use of smart technology to assist radiologists in acquiring CT scan images better personalized for each patient.
The project will evaluate the adoption of smart protocols — automated calculations based on customer-configured dosing parameters — with Bayer CT injectors that provide precision health dosing. By connecting industry and academia, the project aims to drive innovation through exchanging ideas and expertise and enhance patient welfare through access to medical advances. Radiologists employ sophisticated techniques and equipment to deliver precision health.
Talissa Altes, professor and chair of radiology at the MU School of Medicine, leads the study with Bayer, a global enterprise with core competencies in the life science fields of health care and nutrition.
“This software will allow us to customize the contrast dose to the patient and exam to be performed,” said Altes, who also holds the Gwilym S. and Maria Antonia Lodwick Distinguished Professorship in Radiology. “The study will allow us to assess whether personalized contrast dosing improves CT image quality. We are thrilled to partner with Bayer on this important improvement project.”
Part of the study is reviewing images rendered using smart protocols and investigating the clinical outcomes to check the impact of adopting the technology, including any changes in image quality and specific patient factors while gathering insights from radiologists and technicians.
The study also will compare collected data from patients imaged using the smart protocols versus equally matched patients who did not receive them in CT imaging studies using Bayer CT injectors.
The study, “Evaluate adoption of Smart Protocols with CT Injectors during imaging studies,” is another example of how MU uses industry partnerships to deliver the newest treatments to Missourians.
“These types of partnerships relate directly to our mission as a university in that they help patients and families by bringing the latest methods and technologies to Missouri and conducting research around them, all while making an economic impact,” said Roy Hartline, executive director of industry relations at MU. “It also aligns well with MU’s precision health and personalized medicine initiatives.”